Recombinant Mouse ALCAM Fc Chimera Protein, CF Summary
Details of Functionality
Measured by its ability to block adhesion of HuT 78 human cutaneous T cell lymphoma cells to immobilized Recombinant Human CD6 Fc Chimera (Catalog # 627-CD). Recombinant Mouse ALCAM/CD166 Fc Chimera at 10 µg/mL (50 µL/well) blocked >90% of HUT-78 cell adhesion (1 x 106 cells/mL, 50 µL/well) to immobilized recombinant human CD6 Fc Chimera (10 µg/mL, 100 µL/well). Optimal dilutions should be determined by each laboratory for each application.
Mouse myeloma cell line, NS0-derived mouse ALCAM/CD166 protein
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
<0.10 EU per 1 μg of the protein by the LAL method.
82 kDa (monomer). Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
ALCAM (activated leukocyte cell adhesion molecule), designated CD166 and also called MEMD and SC‑1/DM‑GRASP/BEN in the chicken, is a 100 ‑ 110 kDa type I transmembrane glycoprotein and a member of the Ig CAM family within the immunoglobulin superfamily (1). ALCAM is expressed on thymic epithelium, microvascular endothelium, activated lymphocytes and monocytes, and monocyte‑derived dendritic cells (1, 2). Mouse ALCAM cDNA encodes 583 amino acid (aa), including signal peptide (27 aa), extracellular domain (ECD, 500 aa) with two V‑type and three C2‑type Ig‑like domains, transmembrane (22 aa) and cytoplasmic (34 aa) domains (1). Mouse ALCAM ECD shares 98%, 93% and 92% aa sequence identity with rat, human/porcine and bovine/equine ALCAM, respectively. A secreted isoform in endothelial cells that is truncated at aa 133 (sALCAM) antagonizes full‑length ALCAM (3, 4). ALCAM mediates low‑affinity adhesion with itself or the cysteine‑rich scavenger receptor CD6 to regulate T cell development, immunological synapses (IS), and cell migration through endothelial junctions (1 ‑ 11). ALCAM on thymic epithelia mediates adhesion to CD6 on CD4+CD8+ T cells (6). Adhesion of ALCAM‑expressing antigen presenting cells and CD6‑expressing T cells stabilizes the early IS, while later it enhances CD3 effects on T cell proliferation, CD25 expression, and Th1 commitment (2, 7, 8). High ALCAM expression at the blood‑brain barrier in active multiple sclerosis, and its mouse model (EAE), promotes leukocyte migration to the brain (8, 9). High ALCAM expression on human melanoma cell lines appears to be pro‑metastatic, but anti‑metastatic activity has been reported in human breast cancer (3, 10, 11). ALCAM may influence expression or adhesion of the neuronal adhesion molecule NCAM‑L1, both in the developing retina and invasive melanoma (3, 12).
Bowen, M.A. et al. (1995) J. Exp. Med. 181:2213.
Zimmerman, A.W. et al. (2006) Blood 107:3212.
van Kilsdonk, J.W.J. et al. (2008) Cancer Res. 68:3671.
Ikeda, K. and T. Quertermous (2004) J. Biol. Chem. 279:55315.
van Kempen, L.C. et al. (2001) J. Biol. Chem. 276:25783.
Castro, M.A.A. et al. (2007) J. Immunol. 178:4351.
Nair, P. et al. (2010) Clin. Exp. Immunol. 162:116.
Masedunskas, A. et al. (2006) FEBS Lett. 580:2637.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Recombinant Mouse ALCAM Fc Chimera Protein, CF and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.